Scholars Central

Conference abstractPublished 3 Aug 2015

Nischarin, a novel tumor suppressor affects AMP kinase pathway to regulate breast tumorigenesis

Authors: Suresh K Alahari, Fred G Brazda

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The AMP activated kinase protein kinase (AMPK) is a key cellular energy sensor and functions to maintain cellular energy homeostasis. Activation of AMPK allows cells to survive under conditions of energy stress by turning on ATP-producing catabolic pathways and inhibiting ATP-consuming anabolic processes. Mammalian target of rapamycin (mTOR1) is a central growth regulator which is inhibited by AMPK. mTOR1 promotes anabolic processes leading to cell growth. We previously identified and cloned a novel protein that we termed Nischarin, and we have shown that this protein inhibits cell migration, cell invasion and tumor growth in mouse xenograft models. The long term goal of our work is to elucidate the mechanism by which Nischarin regulates breast tumor progression and to identify novel therapeutic approaches to suppress tumor progression in Nischarin lacking breast tumors. In humans, Nischarin is underexpressed in breast cancers. Based on these observations, we hypothesize that Nischarin suppresses breast cancer development and progression. To test this hypothesis we have generated Nischarin conditional knockout mice. Our preliminary data revealed that cells derived from Nischarin null mice exhibited increased migration and invasion. Also, we show that Nischarin lacking tumor cells have low levels of active AMP kinase suggesting that AMPK plays an important role in Nischarin regulation of tumorigenesis. Furthermore, our data indicate that downstream of mTOR1 is affected by manipulation of Nischarin expression. Currently, we are finding ways to up-regulate AMPK in animal models. By gaining a better understanding of the AMPK-mTOR1-Nischarin signaling and their roles in the regulation of mammary growth and metastasis, we will be better equipped to bring cancer therapies to the bedside.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Pathology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Pathology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Suresh K Alahari”
  • BylineArticles whose byline prints “Fred G Brazda”